BRSD-143 / Novartis - LARVOL DELTA

Discovery and characterization of BRSD-143, an orally bioavailable panKRAS inhibitor (AACR 2025) - "In this study, direct comparison of panKRAS, panRAS, and KRAS G12D specific inhibitors suggested equivalent efficacy can be achieved by these different mechanisms. However, further studies are necessary to understand effects on the anti-tumor immune response and which compounds can be best combined with KRAS targeting inhibitors."

Late-breaking abstract • Colorectal Cancer • Leiomyosarcoma • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor • BCL2L1 • EGFR • HRAS • ITGAM • KRAS • NRAS